DURECT (NASDAQ:DRRX) Coverage Initiated at StockNews.com

Investment analysts at StockNews.com initiated coverage on shares of DURECT (NASDAQ:DRRX) in a research report issued on Sunday. The firm set a “sell” rating on the specialty pharmaceutical company’s stock.

Separately, HC Wainwright reissued a “neutral” rating on shares of DURECT in a research report on Thursday, November 14th.

DURECT Stock Performance

Shares of DRRX stock opened at $0.79 on Friday. The firm has a market capitalization of $24.52 million, a PE ratio of -1.30 and a beta of 0.91. The stock has a fifty day simple moving average of $0.83 and a two-hundred day simple moving average of $1.10. DURECT has a 52-week low of $0.70 and a 52-week high of $1.88.

Institutional Investors Weigh In On DURECT

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Jane Street Group LLC lifted its stake in shares of DURECT by 266.0% in the fourth quarter. Jane Street Group LLC now owns 39,196 shares of the specialty pharmaceutical company’s stock worth $29,000 after buying an additional 28,486 shares in the last quarter. Geode Capital Management LLC lifted its stake in DURECT by 4.8% in the 3rd quarter. Geode Capital Management LLC now owns 319,905 shares of the specialty pharmaceutical company’s stock worth $429,000 after purchasing an additional 14,658 shares in the last quarter. Finally, Richmond Brothers Inc. boosted its holdings in shares of DURECT by 12.2% during the 4th quarter. Richmond Brothers Inc. now owns 1,281,176 shares of the specialty pharmaceutical company’s stock worth $961,000 after purchasing an additional 138,920 shares during the last quarter. Institutional investors and hedge funds own 28.03% of the company’s stock.

About DURECT

DURECT Corporation, a biopharmaceutical company, develops medicines based on its epigenetic regulator program. The company's lead product larsucosterol (DUR-928), an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis.